Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. In this phase II study, 14 patients with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m(2)/day as 4...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Albertini, Mark R., Hank, Jacquelyn A., Gadbaw, Brian, Kostlevy, Jordan, Haldeman, Jennifer, Schalch, Heidi, Gan, Jacek, Kim, KyungMann, Eickhoff, Jens, Gillies, Stephen D., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: Springer-Verlag 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3502633/
https://ncbi.nlm.nih.gov/pubmed/22678096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1286-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars